FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Additional Ozempic Indication Approved

[ Price : $8.95]

FDA approves a new indication for Novo Nordisks Ozempic to reduce the risk of worsening kidney disease and cardiovascular death in...

Alzheimers Assay Gets Breakthrough Designation

[ Price : $8.95]

FDA grants Beckman Coulter Diagnostics a breakthrough device designation for its Access p‑Tau217/β-Amyloid 1-42 plasma ...

Stroke Device Cleared for Larger Catheters

[ Price : $8.95]

FDA clears an Imperative Care 510(k) for its Zoom System, a stroke thrombectomy system with .088-inch catheters.

Supernus Wins Label Update for ADHD Drug

[ Price : $8.95]

FDA approves a Supernus Pharmaceuticals label update for attention-deficit/hyperactivity disorder drug Qelbree (viloxazine extende...

Provepharm Recalls Phenylephrine HCl

[ Price : $8.95]

Provepharm recalls one lot of phenylephrine hydrochloride injection, USP, 10 mg/mL due to a customer complaint about visible black...

Once Monthly Leqembi for Alzheimers Approved

[ Price : $8.95]

FDA approves an Eisai/Biogen supplemental BLA for Leqembi (lecanemab-irmb) and its intravenous use once every four weeks as mainte...

Pfizer Pays $60 million to Settle Biohaven Kickbacks

[ Price : $8.95]

Pfizer agrees to pay $59.7 million to resolve allegations that its subsidiary, Biohaven Pharmaceutical, engaged in previous illega...

Vanda Files NDA for Motion Sickness Drug

[ Price : $8.95]

Vanda Pharmaceuticals files an NDA for tradipitant for treating motion sickness.

ALX Oncology Seeking Accelerated OK for Evorpacept

[ Price : $8.95]

ALX Oncology plans to discuss with FDA its path for seeking accelerated approval for CD47-blocker evorpacept based on positive upd...

FDA Approves Medexus Leukemia NDA

[ Price : $8.95]

FDA approves a Medexus NDA for Grafapex (treosulfan) for use with fludarabine as a preparative regimen for allogeneic hematopoiet...